ORIGINAL RESEARCH article
Front. Surg.
Sec. Orthopedic Surgery
Volume 12 - 2025 | doi: 10.3389/fsurg.2025.1483611
This article is part of the Research TopicNew Advances in Perioperative Management of Hip FractureView all 4 articles
Rivaroxaban versus enoxaparin for preventing venous thromboembolism after hip fracture operations: A retrospective cohort study
Provisionally accepted
- Mianyang Third People's Hospital, Mianyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Emerging evidence suggests that rivaroxaban may be effective in preventing venous thromboembolism (VTE) in patients with orthopedic trauma, resulting in fewer bleeding complications. This study was conducted to evaluate the efficacy and safety of rivaroxaban compared with enoxaparin in preventing VTE in patients undergoing hip fracture surgery.Materials and methods: This was a single-center, retrospective cohort study of patients receiving either oral rivaroxaban or subcutaneous injections of enoxaparin for VTE prophylaxis following hip fracture surgery from 2020 to 2023. The data obtained included patient demographics, fracture classification, time to surgery, and procedures performed. The main outcomes assessed were the incidence of VTE, the incidence of hemorrhage events, and the occurrence of death within 30 days of surgery. The daily costs of the two types of medications were also recorded.Results: A total of 166 patients were included. The incidence of VTE was 9.5% in the rivaroxaban group and 26.61% in the enoxaparin group. Hemorrhage events occurred in 9.52% and 1.61% of patients in the rivaroxaban and enoxaparin groups, respectively.No deaths occurred in either group. The average daily cost of rivaroxaban was 26.49±4.77 Chinese yuan, and that of enoxaparin was 75.24±18.54 Chinese yuan.In this cohort study, we found rivaroxaban to be significantly more effective than enoxaparin in reducing postoperative VTE after hip fracture, but it was associated with a greater risk of hemorrhage events. Additionally, the average daily cost of rivaroxaban was lower. To identify patients who will derive the maximum advantages from this treatment, larger prospective studies are needed.
Keywords: Hip Fractures, Venous Thromboembolism, rivaroxaban, Enoxaparin, cost
Received: 20 Aug 2024; Accepted: 21 Apr 2025.
Copyright: © 2025 Zheng, Wang, Chen, Liu, Zhang and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Cong Xiao, Mianyang Third People's Hospital, Mianyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.